Changchun High-tech: Subsidiary Amlodipine Benzenesulfonate Oral Solution Freeze-dried Powder Approved for Marketing by the US FDA

Changchun High-tech announced that the freeze-dried powder for oral solution of amlodipine besylate has been approved for marketing by the U.S. Food and Drug Administration, which is a product developed by Brillian Pharma INC., a subsidiary of the company. This product is suitable for hypertension in patients aged 6 and above, as well as for adults with chronic stable angina, vasospastic angina, and confirmed coronary artery disease by angiography. The freeze-dried powder for oral solution of amlodipine besylate is a 505B2 modified innovative drug developed by Brillian Pharma INC., specifically for children aged 6 and above and adults with hypertension who have difficulty swallowing. It can lower blood pressure in children aged 6 and above and adults, and reduce the risk of fatal and non-fatal cardiovascular events. The approval of this product is beneficial for enriching Brillian's product layout in the U.S. and enhancing the company's competitiveness in the pharmaceutical market.